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Abstract: The validated study of extended-spectrum β-lactamase (ESBL) producing bacteria in
Indonesia is scarce.  Multi-centre study on susceptibility of ESBLs producers is our point of view.
A survey was carried out in three teaching hospitals in Surabaya (Dr. Soetomo), Malang (Dr.
Saiful Anwar) and Semarang (Dr. Kariadi). Clinical ESBL-producers were collected in over
four months period (January to April 2010) up to 300 strains. The susceptibility against 6
antibiotics below were used as a point of view in analysis. As many as 300 isolates were col-
lected, 140 (Surabaya), 85 (Semarang) and 75 (Malang) respectively. The three most prevalent
ESBL producers were: E. coli (42.7%), Klebsiella pneumoniae (47.3%) and Enterobacter spp
(7%). The other 9 strains were: Citrobacter spp, Klebsiella oxytoca, Proteus mirabilis and
Serratia spp. The susceptibility analysis was then performed on the three most prevalent iso-
lates. The sensitivity rate of E. coli, Klebsiella pneumoniae and Enterobacter spp against tested
antibiotics were 3%, 4% and 5% for cefotaxim; 91%, 87% and 90% for Amikacin; 27%, 54% and
43% for Ciprofloxacin; 98%, 93% and 100% for Cefoperason-Sulbactam; 100%, 96% and
100% for Meropenem; 95%, 94% and 86% for Fosfomycin. As a conclusion, we found that
amikacin, cefoperason-sulbactam, meropenem and fosfomycin, are prospective for emperic
therapy in clinical setting of health services where ESBL producing bacteria were prevalent as
causative. J Indon Med Assoc. 2011;61:482-6.
Keywords: Extended Spectrum Beta Lactamases (ESBL), antibiotic, antimicrobial resistance,
sensitivity.
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Abstrak: Data bakteri penghasil ESBL yang tervalidasi di Indonesia sangat terbatas. Studi
multisenter tentang pola dan sensitivitas bakteri penghasil ESBL menjadi kajian utama pada
studi tersebut. Telah dilakukan survei di tiga senter Rumah Sakit Pendidikan di Surabaya (RSUD
Dr.Soetomo), Malang (RSUD Dr. Saiful Anwar) dan Semarang (RSU Dr. Kariadi). Isolat klinik
penghasil ESBL dipisahkan sejak Januari-April 2010 untuk mencapai target sebanyak 300 isolat.
Identifikasi dan uji kepekaan dilakukan sesuai standar di Laboratorium Mikrobiologi RSUD Dr.
Soetomo Surabaya. Enam antibiotik dijadikan kajian dalam studi tersebut, yakni Sefotaksim,
Amikasin, Siprofloksasin, Cefoperason-sulbaktam dan meropenem. Sebanyak 300 isolat berhasil
terkumpul, terdiri 140 (Surabaya), 85 (Semarang) dan 75 (Malang). Isolat terdiri dari E. coli
(42,7%),  Klebsiella pneumoniae (47,3%) and Enterobacter spp (7%). Isolat lain lebih sedikit
(Citrobacter spp, Klebsiella oxytoca, Proteus mirabilis dan Serratia spp). Pada tiga spesies isolat
yang dianalisis menunjukkan bahwa sensitivitas E. coli, Klebsiella pneumoniae and Enterobacter
spp. terhadap antibiotik uji adalah 3%, 4% and 5% terhadap sefotaksim; 91%, 87% dan 90%
for amikasin; 27%, 54% dan 43% untuk siprofloksasin; 98%, 93% and 100% untuk sefoperason-
sulbaktam; 100%, 96% dan 100% untuk Meropenem; serta 95%, 94% and 86% untuk Fosfomisin.
Sebagai kesimpulan, amikasin, sefoperason-sulbaktam, meropenem dan fosfomisin dapat dipakai
sebagai pedoman untuk terapi empirik di rumah sakit dengan insidens bakteri penghasil ESBL
tinggi. J Indon Med Assoc. 2011;61:482-6.
Kata kunci: Extended Spectrum Beta Lactamases (ESBL), antibiotik, reseistensi antimikroba,
sensitivitas.
Introduction
In two decades, bacterial resistance to β-lactam antibi-
otics has risen sherply. It is also predicted that spread among
patients contributes to the increase of bacterial resistance.
The extended-spectrum β-lactamases (ESBLs), enzymes that
hydrolyze the expanded-spectrum cephalosporins, like
ceftazidime and cefotaxime, and/or the monobactam
aztreonam, is one of the most popular ‘virulent enzyme.’ The
first isolate of ESBL producing bacteria was reported in Ger-
many in 1983. Subsequently, many ESBLs, predominantly of
SHV and TEM variants, have been reported in clinical iso-
lates.1 Many type of ESBL enzymes have been identified. In
recent years, cefotaximases of the CTX-M type have be-
come a predominant cause of higher levels resistance.2
Since first identified at the beginning of 1980s, extended-
spectrum β-lactamases (ESBL)-producing microorganisms,
mainly to the family of Enterobacteriaceae, have spread by
nosocomial routes throughout the world. As has been dem-
onstrated for Klebsiella pneumoniae, prevalence in a par-
ticular hospital may vary from 0 % to approximately 50%, and
nationally, in some countries, it may reach approximately 15%.
The ESBL-encoding genes are usually located on large con-
jugative plasmids, which also often carry genes responsible
for resistance to other antibiotics.3,4 The conjugative plas-
mid that carry many genes encoding for antimicrobial resis-
tance, have also found in Dr. Soetomo Hospital, Surabaya.5
Extended-spectrum β-lactamases (ESBLs) are a group
of plasmid-borne enzymes with the ability to hydrolyse third-
generation cephalosporins and monobactams. Most organ-
isms harboring such enzymes remain susceptible to
carbapenems, whereas the activity of ciprofloxacin, cefepime,
and beta-lactam/beta-lactamase inhibitor combinations is
variable. Infections caused by microorganisms producing
ESBLs have become a serious problem for hospitals world-
wide.6
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This study will explore the susceptibility pattern of ESBL
producing microorganisms against 6 antibiotics that are com-
monly used in clinical setting in Indonesia.
Methods
This was a descriptive study to reveal the susceptibil-
ity pattern of ESBL-producing bacteria against 6 commonly
used antibiotics. ESBL producing bacteria was collected from
clinical isolates that were sent to microbiology laboratory in
3 teaching hospitals: Dr. Soetomo Hospital (Surabaya), Dr.
Kariadi Hospital (Semarang) and Dr. Saiful Anwar Hospital
(Malang).  Identification of bacteria and phenotypic confir-
mation of ESBL producer was conducted by two methods.
First, we used double-disk synergy test using disks of
amoxicillin-clavulanic acid, cefotaxime and ceftazidime.1,7
Secondly, we used Phoenix® machine according to the in-
struction of manufacturer.
Susceptibility test against targeted antibiotics was fur-
ther conducted using diffusion method.7 It is due to the
absence of one or more antibiotics pannels in the reagents
provided in automatic machine (Phoenix® or equivalent) and
these antibiotics are commonly used in clinical setting. The
six tested antibiotics were cefotaxime, meropenem, fosfo-
mycin, cefoperazone-sulbactam, amikacin and ciprofloxacin.
Escherichia coli ATCC 25922 was used as a control for sus-
ceptibility testing. Interpretation of susceptibility test was
performed according to CLSI, 2011.7
Table 1. Distribution  of  ESBL   Producing  Bacteria  Among
Centres, Surabaya, Semarang and Malang
Microorganisms Origin  Total (%)
Surabaya Semarang Malang
Citrobacter spp   2 1   0 3 (1%)
Enterobacter spp   4    13   4    21 (7%)
Escherichia coli 61    36 31  128 (42.7%)
Klebsiella oxytoca   1 1   1 3 (1%)
Klebsiella pneumoniae 71    32 39  142 (47.3%)
Proteus mirabilis   1 0   0 1 (0.3%)
Seratia spp   0 2   0 2 (0.7%)
Total 140    85 75  300 (100%)
Results
From January 2010 to April 2010, a total of 300 ESBL
producing isolates have been collected with three most
prevalent ESBL producers were Escherichia coli, Klebsiella
pneumoniae, and Enterobacter spp as seen in Table 1.
The isolates were collected from various specimen as
described in table 2.  Specimen data from Semarang was not
available.
The analysis of susceptibility was performed only on
the three most prevalent bacteria, as seen in Table 3.
The intermediate result of susceptibility against
cefoperazone-sulbactam and amikacin were high, mainly in
two prevalent isolates, E. coli and K. pneumoniae. The in-
termediate result of cefoperason-sulbactam were 25.8% (33
isolates) in E. coli and 35.9% (51 isolates) in K. pneumoniae,
and amikacin were 13.3% (17 isolates) and 9.9% (14 isolates)
for E. coli and for K. pneumonia respectively.
Discussion
The sensitivity rate of cefotaxim and ciprofloxacin in
vitro were low and were not effective for clinical use as the
treatment of ESBL-producing bacteria. The sensitivity of
other four antibiotics, namely meropenem, fosfomycin,
amikacin and combination cefoperazone-sulbactam were still
potential for clinical usage to treat ESBL- producing bacte-
ria.
Table 3. The Sensitivity Pattern of ESBL Pruducing Bacteria Isolated from Three Centres, Dr. Soetomo
Hospital Surabaya, Dr. Kariadi Hospital Semarang and Dr. Saiful Anwar Hospital Malang
Bacteria E coli K. pneumoniae   Enterobacter spp
Total S e n s Sens% Total S e n s Sens% Total S e n s Sens%
Cefotaxime 128     4     3.22 142     6 4.23 21   1     4.8
Meropenem 128 128 100 142 137 96.5 21 21 100
Fosfomycin 128 122   95.31 142 134 94.4 21 18   85.7
Cefo-Sulb 128 125   97.66 142 134 94.4 21 21 100
Amikacin 128 116   90.62 142 123 86.6 21 19   90.5
Ciprofloxacin 128   34   26.56 142   76 53.5 21   9   42.9
Note: Sens=Sensitive; cefo-sulb = cefoperazone-sulbactam combination. All sensitive and intermediate result were included
in sensitive result.
Table 2. The Origin of the Specimen of ESBL Producer Bac-
terial Isolates from Surabaya and Malang
Specimen  Surabaya   Malang  Total
Total    %   Total   % Total  %
Urine   36   25.7 21   28   57 26.5
Blood   24   17.1 13   17.3   37 17.2
Pus   41   29.3 16   21.3   57 26.5
Sputum   20   14.3 17   22.7   37 17.2
Faeces   11     7.9   3     4   14   6.5
Others     8     5.7   5     6.7   13   6.1
Total 140 100 75 100 215   100
Notes: Others=pleural fluid, wound swab, tissue, fistule swab (the data
of specimen from Semarang isolates were not available)
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The sensitivity profile of clinical isolates of ESBL-pro-
ducing bacteria from Surabaya, Semarang and Malang is
consistent with the current worldwide situation, mainly
meropenem.8-12 Meropenem is a reserved antibiotic in clini-
cal setting, and of course fosfomycin, cefoperason-sulbac-
tam and amikacin, are three propective candidates of antibi-
otics  wedas an alternative drugs in clinical usage for comba-
ting ESBL’s producers. Even clinical judgement is very im-
portant for drug selection, mainly in seriously ill patient. As
many studies indicates, cefotaxim and ciprofloxacin are not
effective for clinical usages. Clinical and Laboratory Stan-
dard Institute (CLSI), 20117 has also recommended that the
third generation cephalosporins should be excluded as an
anti-infective drug for ESBL producers, even if the result of
Microbiological culture is sensitive. The author think that
this issue need to be studied further for definitive therapy.
Ciprofloxacin has a certain concern, even though it is not in
similar group of cefotaxim, many studies showed that the
ESBL producers were mostly resistant against ciprofloxacin.
It is predicted by two aspects, the tendency of Health prac-
titioner to change the resistant third generation cepha-
losporin to ciprofloxacin, and also the resistant trait encoded
by plasmid that in combination with other antibiotics, in-
cluding third generation of cephalosporin, and it transfers to
the other bacteria in hospital setting.13,14 In surveillance about
ESBL producers in Dr. Soetomo Hospital, since January to
November 2011 showed that the rate of ESBL producer strain
among E. coli was 45.32% (329 of 726 total isolates) and K.
pneumoniae was 50.28% (360 of 716 isolates).15 It means
that the problem of ESBL in this hospital is increasing, and
the antibiotic policy for increasing the prudent use of antibi-
otic, mainly third ge-neration cephalosporin, is absolutely
needed.
The further analysis of 5 strains of meropenem-resis-
tant K. pneumoniae showed that  3 strains were sensitive
against fosfomycin and cefoperazone-sulbactam, and 2
strains were sensitive against amikacin. This suggested that
fosfomycin, amikacin and cefoperazone-sulbactam could be
an alternative drug for meropenem resistant microbes. In
common clinical setting, meropenem is the first choices for
containment of ESBL producer. This study showed that the
other alternative antibiotic would be the choices, in case of
Table 4. The Intermediate Result of Susceptibility Test in E. coli, K. pneumonia and Enterobacter spp. Against Fosfomycin,
Cefoperason-sulbactam, Amikacin and Ciprofloxacin
Bacteria E coli    K. pneumoniae  Enterobacter spp
Total Sens (%) Inter(%) Total Sens (%) Inter (%) Total Sens (%)     Inter(%)
Fosfomycin 128 116 (90.6)   6 (4.7) 142 125 (88)   9 (6.3)    21 14 (66.7) 4 (19.1)
Cefo-Sulb 128   92 (71.9) 33 (25.8) 142   83 (58.5) 51 (35.9)    21 12 (57.1) 9 (42.9)
Amikacin 128   99(77.3) 17 (13.3) 142 109 (76.8) 14 (9.9)    21 15 (71.4) 4 (19.1)
Ciprofloxacin 128   27 (21.1)   7 (5.5) 142   54 (38) 22 (15.5)    21   7 (33.3) 2 (9.5)
Note: cefo-sulb=Cefoperazone-Sulbactam; Sens = Sensitive; Inter = Intermediate result in susceptibility test. The total quantity of
Enterobacter is too small for further analysis.
resistant against meropenem. However, higher rate of inter-
mediate result should raise an awareness for the possibility
of resistance development in the future.
The two prevalent of specimen were urine and pus, fol-
lowed by blood and sputum. Therefore, urinary tract infec-
tion and wound infection should raise special concern be-
cause ESBL producers were mainly caused by nosocomial
infection. Thus, universal precaution principle should be put
in higher priority during in-patient management, especially
for patients using urethral catheter and/or with exposed
wound. Lower respiratory tract infection should also require
special attention, especially for patient with endotracheal
devices.
Conclusions
ESBL’s producing bacteria are spread among species of
Enterobacteriaceae, the two most frequent were  Escheri-
chia coli and Klebsiella pneumoniae, then followed by
Enterobacter spp and others. The four main specimen of
origin of the ESBL producers were urine, pus, sputum and
blood. Four antibiotics were still potential for clinical usage:
amikacin, meropenem, fosfomycin and combination
cefoperazone-sulbactam. The meropenem-resistant strains
were still sensitive against fosfomycin, amikacin and
cefoperazone-sulbactam. The higher rate of intermediate re-
sult for cefoperason-sulbactam and, in the lesser extend, for
amikacin, need special attention in clinical usage, in the con-
text of the prevention of the development of resistant strains
in the future.
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